ADMA Biologics Inc. (ADMA) Stock Sees Profit Taking At Higher Level: Now What?
ADMA Biologics Inc. (NASDAQ:ADMA) fell 7% after it announced the US FDA had approved VanRX SA25, its in-house aseptic fill-finish machine. According to the company, with the machine operational, it expects significant improvement in gross margins, enhanced inventory-production-cycle times, improved patient supply consistency, and increased visibility and control of commercial-product-lot launches that will create predictable revenue results in the near term. VanRx utilizes a closed isolator design that allows human…